AstraZeneca’s (AZN) Imfinzi has been recommended for approval in the European Union, EU, as monotherapy for the treatment of adults with limited-stage small cell lung cancer, LS-SCLC ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca's Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for ...

AstraZeneca’s (AZ) Imfinzi (durvalumab) has been recommended by the European Medicines Agency’s human medicines committee to treat an aggressive form of lung cancer. The Committee for Medicinal ...

AstraZeneca AZN announced that CHMP has recommended approval for its blockbuster cancer drug Imfinzi (durvalumab) as a monotherapy for treating limited-stage small cell lung cancer (LS-SCLC ...

AstraZeneca, a global, science-led biopharmaceutical company, announced that its Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) as monotherapy for the treatment of ...

Imfinzi recommended for approval in the EU by CHMP as first and only immunotherapy for limited-stage small cell lung cancer Recommendation based on ADRIATIC Phase III trial results which showed a ...

(Alliance News) - AstraZeneca PLC on Monday said Imfinzi has been recommended for approval in the EU as monotherapy for limited-stage small cell lung cancer. The Committee for Medicinal Products ...

(RTTNews) - AstraZeneca (AZN.L, AZN) announced Imfinzi was recommended for approval in the European Union by CHMP as first and only immunotherapy for limited-stage small cell lung cancer.

The CHMP's favorable opinion is based on the results from the ADRIATIC Phase III trial, which indicated a 27% reduction in the risk of death for patients treated with Imfinzi compared to placebo.

AstraZeneca (AZ) has received two separate recommendations from the National Institute for Health and Care Excellence (NICE) for use of its lung cancer drugs Tagrisso (osimertinib) and Imfinzi ...